Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]